Richard Yazbeck, NED Medical - Oncology Embolization Therapies | LSI USA '24

About this Video

• Video Title: Richard Yazbeck, NED Medical - Oncology Embolization Therapies | LSI USA '24
• Channel: LSI - Life Science Intelligence™
• Speakers: Richard Yazbeck
• Duration: 00:07:35

Introduction

This video features Richard Yazbeck from NED Medical presenting at the LSI USA 2024 conference. He discusses NED Medical's innovative embolization therapy for liver cancer, highlighting its unique approach to address tumor hypoxia and improve patient outcomes while offering strong economic potential.

Key Takeaways

• Liver Cancer Problem: Liver cancer is a significant global health issue with high mortality and economic burden. Current embolization therapies are largely ineffective against hypoxic cells.
• NED Medical's Solution: NED Medical has developed a novel embolization therapy that combines bland embolic, chemoembolic, and radioembolic approaches for a more effective, localized treatment.
• Unique Particle Design: Their proprietary particle design allows for high-dose radiation delivery while maintaining flow mechanics similar to red blood cells, improving tumor targeting and reducing side effects.
• Market Opportunity: The market for this therapy is substantial, with a single dose currently reimbursed at approximately $18,000 and low production costs. The company is experiencing strong interest and support from investors and medical professionals.
• Fundraising: NED Medical is seeking seed round funding and preparing for a Series A round.